Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT02243605

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas

Sponsor: National Cancer Institute (NCI)

Conditions Metastatic Ewing Sarcoma Metastatic Osteosarcoma Recurrent Ewing Sarcoma Recurrent Osteosarcoma Stage III Osteosarcoma AJCC v7 Stage IV Osteosarcoma AJCC v7 Stage IVA Osteosarcoma AJCC v7 Stage IVB Osteosarcoma AJCC v7 Unresectable Ewing Sarcoma Unresectable Osteosarcoma

Interventions Cabozantinib S-malate Laboratory Biomarker Analysis

Updated 33 times since 2017 Last updated: Mar 12, 2026 Started: Dec 19, 2014 Primary completion: Jun 30, 2019 Completion: Jul 11, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Ewing Sarcoma and Metastatic Osteosarcoma, this trial is ongoing. The trial is conducted by National Cancer Institute (NCI) and has accumulated 33 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

33 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE2
Sep 2025 — Mar 2026 [monthly]

Active Not Recruiting PHASE2
Jul 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2
Jan 2025 — Jul 2025 [monthly]

Active Not Recruiting PHASE2
Nov 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE2

▶ Show 28 earlier versions

Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Nov 2023 — Jun 2024 [monthly]

Active Not Recruiting PHASE2
Oct 2023 — Nov 2023 [monthly]

Active Not Recruiting PHASE2
Dec 2022 — Oct 2023 [monthly]

Active Not Recruiting PHASE2
Sep 2022 — Dec 2022 [monthly]

Active Not Recruiting PHASE2
Jun 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE2
Dec 2021 — Jun 2022 [monthly]

Active Not Recruiting PHASE2
Sep 2021 — Dec 2021 [monthly]

Active Not Recruiting PHASE2
Jun 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE2
Jan 2021 — Jun 2021 [monthly]

Active Not Recruiting PHASE2
Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2
Oct 2020 — Dec 2020 [monthly]

Active Not Recruiting PHASE2
Oct 2019 — Oct 2020 [monthly]

Active Not Recruiting PHASE2
Aug 2019 — Oct 2019 [monthly]

Active Not Recruiting PHASE2
Jul 2019 — Aug 2019 [monthly]

Active Not Recruiting PHASE2
Jun 2019 — Jul 2019 [monthly]

Active Not Recruiting PHASE2
Mar 2019 — Jun 2019 [monthly]

Active Not Recruiting PHASE2
Feb 2019 — Mar 2019 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2019 — Feb 2019 [monthly]

Recruiting PHASE2
Jun 2018 — Jan 2019 [monthly]

Recruiting PHASE2
Sep 2017 — Jun 2018 [monthly]

Recruiting PHASE2

Status: Suspended → Recruiting
Jun 2017 — Sep 2017 [monthly]

Suspended PHASE2
May 2017 — Jun 2017 [monthly]

Suspended PHASE2
Apr 2017 — May 2017 [monthly]

Suspended PHASE2
Feb 2017 — Apr 2017 [monthly]

Suspended PHASE2
Jan 2017 — Feb 2017 [monthly]

Suspended PHASE2

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bordeaux, France , Dijon, France , Lille, France , Lyon, France , Marseille, France , Nice, France , Paris, France , Saint-Herblain, France , Strasbourg, France , Toulouse, France and 1 more location